Insulet Co. (NASDAQ:PODD) Receives $250.33 Consensus Price Target from Analysts

Shares of Insulet Co. (NASDAQ:PODD) have been assigned a consensus rating of “Moderate Buy” from the sixteen brokerages that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $250.33.

PODD has been the subject of several recent research reports. Stifel Nicolaus raised their price target on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Barclays dropped their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research report on Monday, February 26th. Robert W. Baird raised Insulet from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $180.00 to $238.00 in a research report on Thursday, December 21st. Piper Sandler lowered their price objective on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Finally, JPMorgan Chase & Co. lifted their price objective on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd.

Insider Activity at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the transaction, the director now owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Sunbelt Securities Inc. acquired a new position in shares of Insulet during the first quarter worth about $29,000. Congress Asset Management Co. MA lifted its stake in shares of Insulet by 31.2% during the first quarter. Congress Asset Management Co. MA now owns 39,595 shares of the medical instruments supplier’s stock worth $6,787,000 after purchasing an additional 9,426 shares in the last quarter. Banque Cantonale Vaudoise lifted its stake in shares of Insulet by 79.1% during the first quarter. Banque Cantonale Vaudoise now owns 7,614 shares of the medical instruments supplier’s stock worth $1,305,000 after purchasing an additional 3,362 shares in the last quarter. Mather Group LLC. acquired a new position in shares of Insulet during the first quarter worth about $53,000. Finally, GAMMA Investing LLC increased its position in shares of Insulet by 42.9% during the first quarter. GAMMA Investing LLC now owns 360 shares of the medical instruments supplier’s stock worth $62,000 after acquiring an additional 108 shares during the last quarter.

Insulet Stock Performance

NASDAQ PODD opened at $173.94 on Friday. Insulet has a 1-year low of $125.82 and a 1-year high of $335.91. The company has a market capitalization of $12.18 billion, a P/E ratio of 59.77, a PEG ratio of 3.15 and a beta of 0.98. The business has a 50 day moving average price of $176.32 and a 200 day moving average price of $178.90. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.73. The firm had revenue of $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. Insulet’s quarterly revenue was up 37.9% on a year-over-year basis. During the same period last year, the business posted $0.55 EPS. Sell-side analysts expect that Insulet will post 3.08 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.